+Compare
VXRT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
111.95M

VXRT Vaxart Forecast, Technical & Fundamental Analysis

a vaccine developer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for VXRT with price predictions
07:00 PM EST Dec 04, 2023

VXRT's Stochastic Oscillator is remaining in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for VXRT crossed bullishly above the 50-day moving average on November 14, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VXRT advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VXRT moved out of overbought territory on November 16, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 22, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on VXRT as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VXRT turned negative on November 24, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

VXRT moved below its 50-day moving average on December 05, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VXRT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VXRT broke above its upper Bollinger Band on November 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VXRT entered a downward trend on November 06, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.509) is normal, around the industry mean (20.669). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (129.870) is also within normal values, averaging (329.913).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VXRT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VXRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 11%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 26%. CMND experienced the highest price growth at 3,849%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 64
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

VXRT is expected to report earnings to rise 42.45% to -15 cents per share on February 22

Vaxart VXRT Stock Earnings Reports
Q4'23
Est.
$-0.16
Q3'23
Beat
by $0.07
Q2'23
Beat
by $0.02
Q1'23
Est.
$-0.19
Q4'22
Beat
by $0.05
The last earnings report on November 02 showed earnings per share of -10 cents, beating the estimate of -18 cents. With 585.40K shares outstanding, the current market capitalization sits at 111.95M.
A.I. Advisor
published General Information

General Information

a vaccine developer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
170 Harbor Way
Phone
+1 650 550-3500
Employees
164
Web
https://www.vaxart.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNGAX12.77N/A
N/A
Putnam International Value A
TMSIX32.71N/A
N/A
Thrivent Mid Cap Stock S
GCMTX32.99N/A
N/A
Goldman Sachs Mid Cap Value Inv
MLNIX17.06N/A
N/A
Morgan Stanley Instl Glbl Concntr I
TECHX14.18N/A
N/A
WisdomTree Technology and Inn 100 DgtN/A

VXRT and

Correlation & Price change

A.I.dvisor indicates that over the last year, VXRT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if VXRT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VXRT
1D Price
Change %
VXRT100%
-2.90%
MDGL - VXRT
62%
Loosely correlated
+5.91%
AXON - VXRT
50%
Loosely correlated
-1.96%
ARRY - VXRT
48%
Loosely correlated
+0.81%
ORMP - VXRT
47%
Loosely correlated
-0.93%
SANA - VXRT
45%
Loosely correlated
-1.84%
More

Groups containing VXRT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VXRT
1D Price
Change %
VXRT100%
-2.90%
drugs
(undefined stocks)
44%
Loosely correlated
-0.70%
biotechnology
(undefined stocks)
42%
Loosely correlated
-0.79%
vaccines
(undefined stocks)
28%
Poorly correlated
-1.37%